Inside this Issue
|
The Premier Meeting in Cancer ImmunotherapyMake your plans now to attend North America’s largest meeting focused on cancer immunotherapy and biological therapy. After 2009’s record-breaking programs, don’t miss this year’s spectacular line-up of speakers, sessions, and activities. Join us at the Hyatt Regency Washington on Capitol Hill for:
Preliminary Program Available!Get the details on the SITC programs that are leading progress in this exciting field.
Submit Your Data Now!SITC abstracts represent the top science in the field from around the world. Over 25 countries were represented last year through a record-breaking 235 abstracts. Don’t miss this opportunity to present your data among the field’s elite. Submit your abstract now! Submission deadline: New, Easier RegistrationSITC has launched a new online registration form to make registering for the 2010 programs even easier. If you’re a member or have attended programs in the past, you can simplify the process by using the information and links below:
Reserve Your RoomA block of guest rooms has been reserved at the Hyatt Regency Washington on Capitol Hill. Reserve today to ensure you receive the SITC attendee discount. |
Celebrate 25 Years of SITC History Among the World’s History

© Smithsonian Museum
Join SITC for a special reception at the Smithsonian National Museum of Natural History to celebrate 25 years of innovative science and a future of successes in the immunotherapy / biological therapy field. Network with Annual Meeting delegates as you wander among diamonds and ancient sea creatures in one of the most popular museums in America.
Attendance at the 25th Anniversary & Awards Reception is included with Annual Meeting registration, so don’t delay, register today to ensure your participation in the celebration at this amazing venue.
Take a virtual tour of the Museum.
Share your SITC photos and memories for the Anniversary!
Have some great photos or stories from past SITC meetings? Send your historical photos, memorabilia, and stories to the SITC office for inclusion in some special anniversary features.
James P. Allison, PhD Named Smalley Award Recipient
World-renowned and distinguished cancer immunology researcher, James P. Allison, PhD, from the Memorial Sloan-Kettering Cancer Center has been named as SITC’s 2010 Richard V. Smalley, MD Memorial Award recipient. The Smalley Award recognizes excellence in the field of therapeutic research with biological agents and is a fitting honor for a scientist whose isolation of the T cell receptor protein was heralded by the National Academy of Sciences in 1997 as "one of the three most important findings in immunology in the last twenty years."

Smalley Award Recipient: James P. Allison, PhD
Attend the Annual Meeting to meet Dr. Allison and hear his Keynote Address.
Member Spotlight: James P. Allison, PhD
We asked Dr. Allison, recipient of the 2010 Richard V. Smalley, MD Memorial Award to tell us more about himself and his interest in the field.
Where did you go to school and/or do your training?
I began pursuing a career in basic science at the University of Texas at Austin where I received a BS in Microbiology and a PhD in Biological Sciences. I then went on to the Scripps Clinic and Research Foundation, Department of Molecular Immunology where I did my post-doc fellowship.
What led you into the field of immunotherapy/biological therapy?
Growing up, I was just like any other kid except I probably spent a bit more time with my chemistry set and a little less time on the football field. By the time I reached eighth grade I had decided I was going to be either a scientist or a professor; I wanted to figure out how things worked. My interest in the field of immunology and its potential clinical applications began with a grad school project that involved the discovery of an enzyme which could cure leukemia in mice. My mother and two of her brothers died of cancer. And I thought we could do better so the area of cancer research was particularly interesting to me.
What are your research interests?
I’ve been interested in the mechanisms that regulate the immunological responses of T cells with an emphasis on the development of strategies to manipulate those responses to develop novel tumor immunotherapy approaches. Specifically, we had success blocking CTLA-4 in mouse models and our early-stage clinical trials for patients with melanoma and ovarian cancer have shown promise.
Job to Fill?
Attract the best candidates in cancer immunotherapy and biological therapy by posting your available position on the SITC Job Board. Members get free listings, so be sure to visit the SITC website for more details.
Invite to Supporters & Exhibitors
Want to identify your company as an innovator and thought leader in the global biological/immunotherapy community?
Contact the SITC office for marketing and educational support opportunities available in conjunction with the 2010 programs.